Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided label assessment content is consistent with the supplied FDA label excerpts, accurately reflecting the meningococcal infection risk, vaccination/prophylaxis approach, contraindication, and patient counseling. No contradictions or unsupported safety claims are evident from the text given.
Category Scores
Accurate Statements
VEOPOZ increases susceptibility to serious and life-threatening meningococcal infections (septicemia and/or meningitis) caused by any serogroup, including nongroupable strains.
Supported by 5.1
Meningococcal vaccination does not eliminate the risk of meningococcal infections despite development of antibodies following vaccination.
Supported by 5.1
Complete or update MenACWY and MenB vaccination at least 2 weeks prior to administering the first dose; revaccinate per ACIP recommendations considering duration of VEOPOZ therapy.
Supported by 5.1 and 2.1
If urgent VEOPOZ therapy is indicated in a patient not up to date with both MenACWY and MenB, administer vaccines as soon as possible and provide antibacterial drug prophylaxis; efficacy/duration/regimens for prophylaxis have not been studied in patients receiving complement inhibitors including VEOPOZ.
Supported by 5.1 and 2.1
VEOPOZ is contraindicated in patients with unresolved Neisseria meningitidis infection.
Supported by 4
Patients should carry a Patient Safety Card describing symptoms of meningococcal (or other) infection that should prompt immediate medical evaluation.
Supported by 17
Unsupported Statements
“boxed_warning_check”: boxed warning text could not be determined without boxed warning text.
No boxed warning-specific claim was made that could be verified against the provided label excerpts; this statement is meta-assessment, not directly supported or contradicted by the supplied excerpts.
Contradictions
Important Omissions
No boxed warning evaluation is possible from the provided excerpts because boxed warning text was not included.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated content correctly captures key labeled safety actions and restrictions for meningococcal infection risk (vaccination timing/strategy, prophylaxis in urgent cases, contraindication for unresolved infection) and appropriate patient counseling.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Boxed warning verification cannot be performed because boxed warning text is not present in the provided label excerpts.
Suggested Improvement
Include the label’s boxed warning section text (if applicable) to enable complete on-label verification.